Abstract

Transcription factor (TF) STAT3 contributes to pancreatic cancer progression through its regulatory roles in both tumor cells and the tumor microenvironment (TME). In this study, we performed a systematic analysis of all TFs in patient-derived gene expression datasets and confirmed STAT3 as a critical regulator in the pancreatic TME. Importantly, we developed a novel framework that is based on TF target gene expression to distinguish between environmental- and tumor-specific STAT3 activities in gene expression studies. Using this framework, our results novelly showed that compartment-specific STAT3 activities, but not STAT3 mRNA, have prognostications towards clinical values within pancreatic cancer datasets. In addition, high TME-derived STAT3 activity correlates with an immunosuppressive TME in pancreatic cancer, characterized by CD4 T cell and monocyte infiltration and high copy number variation burden. Where environmental-STAT3 seemed to play a dominant role at primary pancreatic sites, tumor-specific STAT3 seemed dominant at metastatic sites where its high activity persisted. In conclusion, by combining compartment-specific inference with other tumor characteristics, including copy number variation and immune-related gene expression, we demonstrate our method’s utility as a tool to generate novel hypotheses about TFs in tumor biology.

Highlights

  • Transcription factor (TF) STAT3 contributes to pancreatic cancer progression through its regulatory roles in both tumor cells and the tumor microenvironment (TME)

  • We first performed a systematic analysis to investigate the differential expression of all human TFs; our analysis included 1164 human TFs expressed in pancreatic cancer and confirmed STAT3 as one of the TFs being more highly expressed in the tumor microenvironment than in cancer cells (Fig. 1A)

  • We utilized the compartment-specific STAT3 activities to evaluate the role of STAT3 in prognosis, immune infiltration, and metastasis in pancreatic cancer (Fig. 1C)

Read more

Summary

Introduction

Transcription factor (TF) STAT3 contributes to pancreatic cancer progression through its regulatory roles in both tumor cells and the tumor microenvironment (TME). We developed a novel framework that is based on TF target gene expression to distinguish between environmental- and tumor-specific STAT3 activities in gene expression studies. Using this framework, our results novelly showed that compartment-specific STAT3 activities, but not STAT3 mRNA, have prognostications towards clinical values within pancreatic cancer datasets. To therapeutically modify the immune milieu of cancer tissues, immune checkpoint blockade therapies have been used Such therapies have experienced progress in the treatment of melanoma and lung cancer[7,8,9], but have had lackluster success in treating pancreatic cancer[7,10,11]. STAT3 is required for the evolution of pancreatic neoplasia into pancreatic cancer in the presence of KRAS mutations[31,32,33]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call